It's my belief that Market Cap is related to the perception of when approval, and therefore revenue, can be anticipated. The market cap should move up dramatically as more becomes known, from the issuance of the Journal, and then a filing is made with at least one, or perhaps more, of the regulators. In anticipating approval short term, the market cap ought to be in at least the billion dollar range, then post approval rising revenue will take it substantially higher.
It's my belief that if the perception is that our drugs will eventually be approved for many diseases, the P/E for the company should be in the 30 area, IE on the high side of the revenue multiples. I certainly believe that with approvals our revenue will go into multiple billions annually, with a P/E of 30 a market cap at or near triple digit billions is certainly in the realm of possibilities. It won't happen instantly, but if the company isn't bought out, it should happen in time.
Gary
News 
Market Data 
Discover 
